S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:ATNX

Athenex (ATNX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.20
▼
$1.52
52-Week Range
N/A
Volume
1.88 million shs
Average Volume
194,316 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

ATNX stock logo

About Athenex (NASDAQ:ATNX) Stock

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.


ATNX Stock News Headlines

July 31, 2023 | bizjournals.com
Athenex assets sold in bankruptcy auction; top executives dismissed
June 11, 2023 | fool.com
Athenex (NASDAQ: ATNX)
September 27, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
June 1, 2023 | bizjournals.com
Buffalo's drug development scene expected to continue in Athenex's wake
May 17, 2023 | bizjournals.com
Athenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-August
May 16, 2023 | uk.finance.yahoo.com
Athenex, Inc. (ATNX) stock price, news, quote & history – Yahoo Finance
May 16, 2023 | msn.com
Buffalo Billion project Athenex files for Chapter 11 bankruptcy
May 15, 2023 | msn.com
Athenex files Chapter 11
September 27, 2023 | Chaikin Analytics (Ad)
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
May 15, 2023 | bizjournals.com
Athenex files for bankruptcy, announces plans to sell assets
May 15, 2023 | msn.com
Why Athenex (ATNX) Stock Is Getting Obliterated Monday
May 15, 2023 | finance.yahoo.com
Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge
May 15, 2023 | marketwatch.com
Athenex Shares Tumble Premarket After Chapter 11 Filing >ATNX
May 15, 2023 | msn.com
Why Is Athenex (ATNX) Stock Down 54% Today?
May 15, 2023 | markets.businessinsider.com
Athenex Files For Chapter 11 Bankruptcy
May 14, 2023 | news.yahoo.com
Drugmaker Athenex voluntarily files for U.S. Chapter 11 proceedings
May 14, 2023 | finance.yahoo.com
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
May 10, 2023 | bizjournals.com
Pine Pharmaceuticals assumes part of Athenex’s business and 50 workers
May 1, 2023 | finance.yahoo.com
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
April 24, 2023 | finance.yahoo.com
Athenex, Inc. (ATNX) Stock Historical Prices & Data - Yahoo Finance
April 18, 2023 | bizjournals.com
California-based Biomed Industries offers to buy Athenex
March 23, 2023 | finance.yahoo.com
Athenex (ATNX) Upgraded to Buy: Here's Why
February 14, 2023 | finance.yahoo.com
Athenex Announces a Reverse Stock Split
January 3, 2023 | finance.yahoo.com
Athenex Announces MHRA Decision on Oral Paclitaxel
December 31, 2022 | msn.com
Athenex to close Clarence plant, lay off 92 employees
December 20, 2022 | finance.yahoo.com
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
December 16, 2022 | finance.yahoo.com
Athenex Exits 503B Sterile Compounding Business
See More Headlines
Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

ATNX Company Calendar

Last Earnings
11/04/2021
Today
9/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATNX
CUSIP
N/A
CIK
1300699
Web
www.athenex.com
Phone
(716) 427-2950
Fax
N/A
Employees
652
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($15.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-103,430,000.00
Net Margins
-86.31%
Pretax Margin
-95.92%
Return on Equity
-727.79%
Return on Assets
-44.44%

Debt

Debt-to-Equity Ratio
3.08
Current Ratio
1.09
Quick Ratio
0.72

Sales & Book Value

Annual Sales
$102.82 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.07) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
8,660,000
Free Float
7,866,000
Market Cap
$1.76 million
Optionable
Optionable
Beta
1.36
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Yiu Nam Lau
    Chairman & Chief Executive Officer
  • Jeff Yordon
    COO & President-Athenex Pharmaceutical Division
  • Joe Annoni
    Chief Financial Officer
  • Darrel P. Cohen
    Chief Medical Officer
  • William Zuo
    President-China Operations

Key Competitors

View All Competitors













ATNX Stock - Frequently Asked Questions

Should I buy or sell Athenex stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ATNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View ATNX analyst ratings or view top-rated stocks.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.08. The company earned $32.30 million during the quarter, compared to analyst estimates of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period last year, the business posted ($0.44) earnings per share.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

How much money does Athenex make?

Athenex (NASDAQ:ATNX) has a market capitalization of $0.00 and generates $102.82 million in revenue each year. The company earns $-103,430,000.00 in net income (profit) each year or ($15.88) on an earnings per share basis.

How many employees does Athenex have?

The company employs 652 workers across the globe.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The official website for the company is www.athenex.com. The company can be reached via phone at (716) 427-2950 or via email at stevenrubis@athenex.com.

This page (NASDAQ:ATNX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -